Compare Meta Platforms Inc (META) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Sana Biotechnology Inc — how do they compare? Meta Platforms Inc trades at $647.56 (market cap $1.64T), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Meta Platforms Inc is far larger — about 1876.8× Sana Biotechnology Inc's market cap, and Meta Platforms Inc pays a 0.33% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| META | SANA | |
|---|---|---|
Market Cap | $1.64T | $873.84M |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $5.92 |
52-Week Low | $525.72 | $2.68 |
Enterprise Value | $1.65T | $848.03M |
Dividend Yield | 0.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $646.27, up 0.04% with a bullish technical signal and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $10.44 significantly exceeding expectations of $6.70. Revenue growth remains strong at $201B for 2025, while maintaining impressive profitability with 32.84% net income margin. Recent AI developments including Muse Spark launch and a $21B partnership with CoreWeave highlight continued innovation momentum.
The outlook remains positive with analyst consensus price target of $817.32 representing 26% upside potential. Key opportunities include AI monetization and infrastructure leadership, while risks involve regulatory lawsuits and high capital expenditures. Wall Street sentiment is strongly bullish with 79% buy ratings, though investors should monitor legal challenges and competitive pressures in the evolving AI landscape.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
